Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.48 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.44 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.44 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111413 | 0.87 | NPC1 (0.59) | NPC1LMNAMAPTHTTKMT2A | |
| SCHEMBL4112124 | 0.84 | NPC1 (0.61) | NPC1LMNAMAPTHTTKMT2A | |
| SCHEMBL4104736 | 0.83 | NPC1 (0.71) | NPC1LMNAMAPTHTTKMT2A | |
| SCHEMBL4117959 | 0.81 | NPC1 (0.74) | NPC1LMNAMAPTHTTKMT2A | |
| SCHEMBL4110382 | 0.80 | RAB9A (0.59) | NPC1LMNAMAPTHTTKMT2A | |
| SCHEMBL4115731 | 0.80 | MAPT (1.00) | NPC1LMNAMAPTHTTKMT2A | |
| SCHEMBL4117216 | 0.79 | NPC1 (0.63) | NPC1LMNAMAPTHTTKMT2A | |
| SCHEMBL18615367 | 0.79 | CDK8 (0.61) | NPC1LMNAMAPTHTTKMT2A | |
| SCHEMBL4113342 | 0.79 | MAPT (0.50) | NPC1LMNAMAPTHTTKMT2A | |
| SCHEMBL18615379 | 0.78 | MAPT (0.57) | NPC1LMNAMAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | NPC1 927/4885LMNA 4283/4885MAPT 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.